Research Article

In Silico Prediction of Aridanin as a Potential Anticancer and Antibacterial Agent

Volume: 29 Number: 2 January 21, 2026
TR EN

In Silico Prediction of Aridanin as a Potential Anticancer and Antibacterial Agent

Abstract

Aridanin, 3-O-[β-D-glucopyranosyl-(2’-acetamido)]-3β-olean-12-en-28-oic acid, isolated from Tetrapleura tetraptera, is reported to have good potential for use as an anticancer drug, especially against resistant cancers. In an in-silico study, the binding modes of aridanin/doxorubicin and 6 enzymes involved in cancer chemotherapy, as well as 3 antibacterial enzymes, were investigated. Also, predictions on its possible bioactivities and pharmacokinetic properties were made. Aridanin/doxorubicin enzyme interactions were determined using molecular docking and molecular dynamics simulations to attempt an explanation for its anticancer activity. Predictions of bioactivity, pharmacokinetic properties, and bioavailability scores of the molecule were calculated using PASS, SwissADME, and pKCSM. The results corroborated previous experimental data, with MolDock scores comparable to those of the standard drug and relatively higher binding energies. Accordingly, aridanin theoretically is a better inhibitor of the studied enzymes than doxorubicin. The highest inhibition recorded binding energies of -9.9, -9.2, and -10.9 kcal/mol for topoisomerase II alpha, DNA methyltransferase, and DD-peptidase, respectively. This suggests that aridanin’s anticancer property may be more through interference with DNA-related proteins. In addition, ADMET/PASS anticipated that aridanin is not toxic, has a good bioavailability score of 0.56, and may display several different bioactivities. Consequently, aridanin is a potent chemotherapeutic agent against resistant cancers and bacteria that should be considered for clinical studies.

Keywords

Project Number

3240328525

Thanks

We acknowledge support from TÜBİTAK through grant no: 3240328525. We are also thankful to Pr. Dr. Shaheen F. and the ICCBS where the spectra were recorded.

References

  1. Abdullahi, S. H., Adamu, U., Adamu, S. G., Sani, U., & and Umar, A. B. (2022). Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors. Egyptian Journal of Basic and Applied Sciences, 9(1), 180-204. https://doi.org/10.1080/2314808X.2022.2050115
  2. Aderibigbe, A., Iwalewa, E. O., Adesina, K. S., & Agboola, I. O. (2011). Anxiolytic effect of aridanin isolated from Tetrapleura tetraptera in mice. International Journal of Biological and Chemical Sciences, 4. https://doi.org/10.4314/ijbcs.v4i5.65523
  3. Adesina, S., Iwalewa, E. O., & Johnny, I. (2016). Tetrapleura tetraptera Taub- Ethnopharmacology, Chemistry, Medicinal and Nutritional Values- A Review. British Journal of Pharmaceutical Research, 12, 1-22. https://doi.org/10.9734/BJPR/2016/26554
  4. Adesina, S. K., & Reisch, J. (1985). A triterpenoid glycoside from Tetrapleura tetraptera fruit. Phytochemistry, 24(12), 3003-3006. https://doi.org/https://doi.org/10.1016/0031-9422(85)80044-3
  5. Alminderej, F., Bakari, S., Almundarij, T. I., Snoussi, M., Aouadi, K., & Kadri, A. (2020). Antioxidant Activities of a New Chemotype of Piper cubeba L. Fruit Essential Oil (Methyleugenol/Eugenol): In Silico Molecular Docking and ADMET Studies. Plants (Basel), 9(11). https://doi.org/10.3390/plants9111534
  6. Altshuler, R. D., Minasian, L. M., Schweppe, C. A., & Kadan-Lottick, N. S. (2025). Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023). JNCI Cancer Spectrum, 9(3). https://doi.org/10.1093/jncics/pkaf039
  7. Anyamele, T., Onwuegbuchu, P. N., Ugbogu, E. A., & Ibe, C. (2023). Phytochemical composition, bioactive properties, and toxicological profile of Tetrapleura tetraptera. Bioorganic Chemistry, 131, 106288. https://doi.org/10.1016/j.bioorg.2022.106288
  8. Bandyopadhyay, D., Lopez, G., Cantu, S., Balboa, S., Garcia, A., Silva, C., & Valdes, D. (2018). Key Enzymes in Cancer: Mechanism of Action and Inhibition With Anticancer Agents.

Details

Primary Language

English

Subjects

Plant Biochemistry , Pharmacology and Pharmaceutical Sciences (Other)

Journal Section

Research Article

Early Pub Date

January 21, 2026

Publication Date

January 21, 2026

Submission Date

January 24, 2025

Acceptance Date

June 16, 2025

Published in Issue

Year 2026 Volume: 29 Number: 2

APA
Godloves Fru, C., Başar, Y., Chongong, M. A., Yenigün, S., Ayimele, G. A., & Demirtas, İ. (2026). In Silico Prediction of Aridanin as a Potential Anticancer and Antibacterial Agent. Kahramanmaraş Sütçü İmam Üniversitesi Tarım Ve Doğa Dergisi, 29(2), 265-284. https://doi.org/10.18016/ksutarimdoga.vi.1623765


International Peer Reviewed Journal
Free submission and publication
Published 6 times a year



88x31.png


KSU Journal of Agriculture and Nature

e-ISSN: 2619-9149